Scott Gottlieb Quotes
The ACA purposely constrains choice as a top-down means of cost control. Obamacare isn't a consumer-driven, high-deductible scheme. It's hollow coverage.
Gottlieb, Scott. "Obamacare's Premiums Are High Because Its Coverage Is Hollow." Forbes, 26 Oct. 2016.
This statement, along with {633806}, was made by the President dozens of times. It is a quotation that had more influence on the political status of the nation than most others. Why Obama made such an absolute statement has been a mystery since, but the statement could not possibly have been literally true as long as the insurance companies had the right to cancel existing plans. When they did, they often laid the blame on the Obamacare rules, when the rules had grandfathered them in, but these were policies that the insurance companies saw as not sufficiently profitable in the new health insurance environment. The Republicans and many Democrats castigated Obama as millions of American lost their health insurance despite the President’s oft stated promise. Though not recognized at the time, the statement turned out to have been a huge gaff.
Scott Gottlieb is an American physician and investor who served as the 23rd commissioner of the Food and Drug Administration (FDA) from 2017 until April 2019. He is presently a resident fellow at the conservative think tank the American Enterprise Institute (AEI), a partner at the venture capital firm New Enterprise Associates (NEA), a member of the board of directors of drug maker Pfizer, Inc, a member of the board of directors of Illumina, Inc., and a contributor to the cable financial news network CNBC. Before becoming FDA commissioner, he was a clinical assistant professor at New York University School of Medicine, the FDA deputy commissioner for medical and scientific affairs, a venture partner with New Enterprise Associates, a member of the policy board of the Leukemia & Lymphoma Society, a senior official at the Centers for Medicare and Medicaid Services, and a member of the Federal Health Information Technology Policy Committee, which advises the United States Department of Health and Human Services on healthcare information technology. He was previously a resident fellow at AEI from 2007 to 2017 prior to joining the FDA as commissioner in May 2017.
